Hyperphosphatemia, or elevated blood phosphorus, is a prevalent issue in chronic kidney disease patients on dialysis, affecting over 80% of this population and linked to higher morbidity and mortality. Clinical guidelines recommend reducing phosphate levels to the 2.5 to 4.5?mg/dL range, and yet an estimated 75% of U.S. dialysis patients remain uncontrolled.
The company we are profiling today is Unicycive Therapeutics Inc. (UNCY), which is developing a treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.